Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3789-3797

  Nessa, Meher U ^a   Beale, Philip ^b   Chan, Charles ^b   Yu, Jun Q ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Cisplatin; Drug combination; Drug resistance; Oxaliplatin; Quercetin; Synergism; Thymoquinone

Indexed keywords

CISPLATIN; OXALIPLATIN; QUERCETIN; THYMOQUINONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CHEMICAL STRUCTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DNA BINDING; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; NITROBLUE TETRAZOLIUM TEST; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; BENZOQUINONES; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; QUERCETIN; TUMOR CELLS, CULTURED;

EID: 83055161837     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gallion HH, Pieretti M, DePriest PD and van Nagell JR Jr.: The molecular basis of ovarian cancer. Cancer 76(10 Suppl): 1992-1997, 1995.
2. Schuijer M, Berns EM, Schuijer M and Berns EMJJ: TP53 and ovarian cancer. Hum Mutat 21(3): 285-291, 2003. (Pubitemid 36292970)
3. Chan MM and Fong D: Overcoming ovarian cancer drug resistance with phytochemicals and other compounds. In: Drug Resistance Neoplasms. Varie EG (ed.). New York, Nova Science Publishers, 2007.
4. Sarkar FH, Li Y, Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66(7): 3347-3350, 2006.
5. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH and Mohammad RM: In review on Molecular and Therapeutic Potential of Thymoquinone in Cancer. Nutr Cancer 62(7): 938-946, 2010.
6. Solomon Leigh A, Ali S, Banerjee S, Munkarah Adnan R, Morris Robert T and Sarkar Fazlul H: Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res 1(1): 1-11, 2008.
7. Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H, Chan MM, Fong D, Soprano KJ, Holmes WF and Heverling H: Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194(1): 63-70, 2003. (Pubitemid 35424228)
8. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71(10): 1397-1421, 2006.
9. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, Schneider-Stock R, Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A and Schneider-Stock R: Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 25(4): 857-866, 2004.
10. Gali-Muhtasib H, Roessner A, Schneider-Stock R, Gali-Muhtasib H, Roessner A and Schneider-Stock R: Thymoquinone: a promising anticancer drug from natural sources. Int J Biochem Cell Biol 38(8): 1249-1253, 2006.
11. Yunos Nurhanan M, Beale P, Yu Jun Q and Huq F: Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in the Killing of Human Ovarian Cancer Cells. Anticancer Res 31(4): 1131-1340, 2011.
12. Alshehri A, Beale P, Yu JQ, Huq F, Alshehri A, Beale P, Yu JQ and Huq F: Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines. Anticancer Res 30(11): 4547-4553, 2010.
13. Yunos NM, Beale P, Yu JQ, Strain D and Huq F: Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines. Anticancer Res 30(10): 4025-4038, 2010.
14. 2]. Indian J Chem 8: 193-194, 1970.
15. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63, 1983.
16. Chou T-C: Relations between inhibition constants and fractional inhibition on enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 10(2): 235-427, 1974.
17. Chou T-C: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59(2): 253-276, 1976.
18. Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E and Formento ML: Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anticancer Res 18(4C): 3113-3117, 1998. (Pubitemid 28388825)
19. Roberts JD, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L and Farrell N: Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem 77(1-2): 47-50, 1999. (Pubitemid 30089081)
20. Bowtell DDL: Rapid isolation of eukaryotic DNA. Anal Biochem 162(2): 463-475, 1987.
21. Holford J, Beale PJ, Boxall FE, Sharp SY and Kelland LR: Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 36(15): 1984-1990, 2000.
22. Al-Eisawi Z, Beale P, Chan C, Yu JQ and Huq F: Modulation of Cisplatin Cytotoxicity due to its combination with Bortezomib and the nature of its administration. Anticancer Res 31(9): 2757-2762, 2011.